Trellus Management Company’s Pacific Biosciences PACB Stock Holding History

Trellus Management Company’s Portfolio PACB Stock Details PACB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	$927K	Buy	111,000 +22,500	+25%	+$257K	1.27%	16
2023 Q2	$1.18M	Hold	88,500	–	–	1.45%	12
2023 Q1	$1.02M	Buy	88,500 +20,000	+29%	+$199K	1.21%	16
2022 Q4	$560K	Sell	68,500 -41,500	-38%	-$358K	0.71%	27
2022 Q3	$639K	Buy	110,000 +30,000	+38%	+$172K	0.78%	21
2022 Q2	$354K	Buy	80,000 +40,000	+100%	+$243K	0.43%	36
2022 Q1	$364K	Hold	40,000	–	–	0.21%	41
2021 Q4	$818K	Buy	40,000 +21,500	+116%	+$519K	0.54%	34
2021 Q3	$473K	Buy	+18,500	New	+$548K	0.34%	56
2019 Q1	–	Sell	-111,000	Closed	-$821K	–	62
2018 Q4	$821K	Sell	111,000 -417,415	-79%	-$2.64M	1.86%	18
2018 Q3	$2.86M	Sell	528,415 -171,585	-25%	-$736K	4.13%	6
2018 Q2	$2.48M	Sell	700,000 -75,000	-10%	-$208K	3.66%	5
2018 Q1	$1.59M	Buy	775,000 +125,000	+19%	+$325K	2.89%	10
2017 Q4	$1.72M	Buy	650,000 +125,000	+24%	+$438K	2.34%	8
2017 Q3	$2.76M	Hold	525,000	–	–	3.78%	5
2017 Q2	$1.87M	Buy	525,000 +210,800	+67%	+$850K	2.75%	9
2017 Q1	$1.62M	Buy	314,200 +6,000	+2%	+$29.4K	2.46%	7
2016 Q4	$1.17M	Buy	308,200 +83,200	+37%	+$605K	1.72%	14
2016 Q3	$2.02M	Hold	225,000	–	–	2.92%	5
2016 Q2	$1.58M	Buy	225,000 +63,600	+39%	+$581K	2.57%	8
2016 Q1	$1.37M	Buy	161,400 +63,550	+65%	+$625K	2.39%	8
2015 Q4	$1.28M	Sell	97,850 -6,950	-7%	-$62.3K	1.89%	13
2015 Q3	$384K	Buy	104,800 +9,000	+9%	+$44K	0.56%	49
2015 Q2	$552K	Buy	95,800 +8,400	+10%	+$48.6K	0.62%	51
2015 Q1	$510K	Buy	+87,400	New	+$603K	0.61%	48
2014 Q4	–	Sell	-34,283	Closed	-$168K	–	101
2014 Q3	$168K	Buy	+34,283	New	+$179K	0.14%	102

Other funds holding PACB

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Madrone Advisors Menlo Park, California $1.03B AUM 20.53% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

JSP

Jackson Square Partners Larkspur, California $247M AUM 20.29% 1-Year Est. Return

Trellus Management Company's PACB Position: Q3 2023 in Review

Trellus Management Company increased its Pacific Biosciences (PACB) stake by 25% in Q3 2023, buying an estimated $257K and bringing the position to 111,000 shares worth $927K. The position accounts for 1.27% of the portfolio, ranked #16.

Trellus Management Company first reported a position in PACB in Q3 2014 and has held it in 26 quarters since. The position peaked at $2.86M in Q3 2018. 274 funds tracked by Wall St. Rank hold PACB as of Q3 2023.

Trellus Management Company held 111,000 shares of Pacific Biosciences worth $927K as of Q3 2023.
Trellus Management Company bought 22,500 Pacific Biosciences shares in Q3 2023, an estimated $257K.
Pacific Biosciences made up 1.27% of Trellus Management Company's portfolio in Q3 2023, its #16 holding.
Trellus Management Company first reported a position in Pacific Biosciences in Q3 2014 and has held it in 26 quarters since.
Trellus Management Company's Pacific Biosciences position peaked at $2.86M in Q3 2018.
274 funds tracked by Wall St. Rank held Pacific Biosciences as of Q3 2023.

Based on Trellus Management Company's 13F filing for Q3 2023, filed 24 Oct 2023.